Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Standard Care

Core clinician-reference fields are available or not applicable.

Participants treated with tirzepatide for weight management.

Tirzepatide Treatment

In SURMOUNT-1, 81.8 % of participants treated with tirzepatide (pooled 10 mg/15 mg) shifted at least one BMI category lower.

Participants receiving standard care for obesity management.

The SURMOUNT clinical trials assessed in these analyses were SURMOUNT-1 (NCT04184622) and SURMOUNT-4 (NCT04660643).

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Tirzepatide improves cardiometabolic health in obesity.

Comparator Interventions

Participants received once-weekly tirzepatide treatment.

Participants were randomly assigned to receive once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) or one of the following comparator interventions: semaglutide (1 mg), insulin degludec, or placebo.

Participants received either semaglutide, insulin degludec, or placebo.

Tirzepatide improves glycemic control in early-onset type 2 diabetes

Placebo Control

Participants receiving once weekly tirzepatide treatment for type 2 diabetes.

Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).

Participants receiving placebo treatment.

The primary efficacy measure of HbA1c reduction from baseline was superiority of tirzepatide compared with placebo or noninferiority of tirzepatide compared with active comparators.

Tirzepatide improves weight loss in adults with type 2 diabetes

Structured population data were available for 2 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

2 supporting studies do not have a displayable topic-matched quantitative effect.

1 supporting study lacks usable structured population information.

Structured population data were available for 11 of 11 supporting studies. Diabetes type was heterogeneous: 9 studies with type 2 diabetes, 1 studies with type 1 diabetes. 11 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, usual_care.

9 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Structured population data were available for 5 of 5 supporting studies. 3 studies described participants with type 2 diabetes. 5 studies described adult participants.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: baseline_within_group, unknown_unresolved, usual_care.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group.

Structured population data were available for 5 of 5 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Evidence uses heterogeneous comparison contexts: unknown_unresolved, usual_care.

Structured population data were available for 9 of 9 supporting studies. 3 studies described participants with type 2 diabetes. 7 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, other, unknown_unresolved, usual_care.

4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 3 studies described adult participants.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 9 of 9 supporting studies. 9 studies described participants with type 2 diabetes. 9 studies described adult participants.

Tirzepatide × Waist circumference

Available supporting studies

Tirzepatide improves cardiometabolic health in obesity.

Tirzepatide improves glycemic control in early-onset type 2 diabetes

Tirzepatide improves weight loss in adults with type 2 diabetes